Company Overview - Jingfeng Medical, established in 2017, focuses on the research and development of surgical robots, aiming to design, develop, and manufacture surgical robots. The company currently has three products at different stages of development, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots [8][21]. Product Pipeline - The product lineup includes two core products: Jingfeng's multi-port laparoscopic surgical robot and single-port laparoscopic surgical robot. The company has developed a comprehensive technology platform with seven core proprietary technology modules [8][24]. - The MP1000 is the first laparoscopic surgical robot approved for multiple surgical specialties, while the SP1000 is the first single-port laparoscopic surgical robot approved by the National Medical Products Administration (NMPA) for gynecological surgeries [21][22]. Market Size - The global surgical robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 18.9% from 2019 to 2024, 12.0% from 2024 to 2030, and 22.4% from 2030 to 2033. The market size is expected to reach approximately $84.19 billion by 2033 [15][19]. Industry Position - Jingfeng Medical has achieved significant milestones, including obtaining NMPA approval for the MP1000 in December 2022 and expanding its application range to gynecology, general surgery, and thoracic surgery by August 2023. The company has also received approval for the upgraded MP1000 Plus model in October 2023 [21][22]. - As of the latest available data, over 12,000 robotic-assisted clinical surgeries in China have been performed using the company's multi-port laparoscopic surgical robot, and over 2,000 surgeries using the single-port laparoscopic surgical robot [23][24]. Financial Data - The total revenue for the company is projected to be 1.60 billion RMB in 2023, with forecasts of 1.49 billion RMB in 2024 and 0.48 billion RMB by June 30, 2025. The financial figures indicate a growing trend in revenue generation [37][38].

Group 1 - The pharmaceutical sector showed weakness on December 30, with the Hang Seng Hong Kong-Shanghai Innovation Drug Select 50 Index down by 0.56% [1] - Among the constituent stocks, Gan Li Pharmaceutical, Hao Yuan Pharmaceutical, and Junshi Biosciences saw the highest gains, while Baijia Shenzhou, WuXi AppTec, and Kailai Ying experienced declines [1] - The Tianhong Innovation Drug ETF (517380), which tracks the Hang Seng Hong Kong-Shanghai Innovation Drug Select 50 Index, has a total fund size of 1.381 billion yuan and has seen a share increase of over 308% year-to-date, with the latest share count at 1.848 billion [1] Group 2 - Huadong Medicine announced that its subsidiary received a notice from the Ministry of Agriculture and Rural Affairs regarding the acceptance of a new veterinary drug registration application for HDM7006, aimed at weight management in adult obese cats [1] - Xinda Securities believes that the spring market is about to start, recommending attention to emerging pharmaceutical industries such as brain-computer interfaces, surgical robots, and AI applications, with a long-term focus on innovation and international expansion in the medical investment sector [1] - Huaxi Securities points out that the innovation drug industry chain will be the main line of the pharmaceutical sector by 2026, highlighting two key trends: marginal improvement in overseas demand and reversal of domestic demand challenges [2]

Group 1 - The company, Jingfeng Medical, has launched an IPO with a global offering of 27.7222 million shares, including 2.7723 million shares for Hong Kong and 24.9499 million shares for international placement, along with an over-allotment option of 4.1583 million shares [1] - The share price is set at HKD 43.24, with expected fundraising of HKD 1.1166 billion if the over-allotment option is not exercised, and up to HKD 1.2892 billion if it is exercised [1] - The company is focused on the surgical robotics sector, having developed multiple models of surgical robots for minimally invasive and non-invasive surgeries since its establishment in 2017 [1] Group 2 - Jingfeng Medical's core products, the Jingfeng® multi-port and single-port surgical robots, commenced commercialization in December 2022 and December 2024, respectively, with 61 global sales agreements signed by June 30, 2025 [2] - The company has completed over 12,000 robotic-assisted clinical surgeries using the multi-port robot and over 2,000 using the single-port robot [2] - Financial data shows revenues of CNY 48.042 million for 2023, CNY 160 million for 2024, and CNY 149 million for the first half of 2025, with a nearly fourfold increase in revenue for the first half of 2025 compared to the same period in 2024 [2] - The gross profit for the first half of 2025 was CNY 93.85 million, representing a year-on-year growth of nearly 390%, making it the industry leader [2] - The company has received support from notable investors aligned with its vision for surgical robotics, including Abu Dhabi Investment Authority, UBS Asset Management, Tencent, and others [2]

Group 1 - The company plans to globally offer 27.72 million H-shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 43.24 per share, with a trading unit of 100 shares, and the shares are expected to start trading on January 8, 2026 [1] - The company was established in 2017 and specializes in advanced surgical robots, focusing on the design, development, and manufacturing of surgical robots [2] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of USD 75 million (approximately HKD 583.5 million) of the offered shares [3] - The cornerstone investors include notable entities such as Abu Dhabi Investment Authority, UBS Asset Management, and Tencent Holdings [3] - Assuming no exercise of the over-allotment option and a share price of HKD 43.24, the net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion [4] Group 3 - The company plans to allocate the net proceeds as follows: approximately 23% for the development of the multi-port laparoscopic surgical robot, 19% for the single-port laparoscopic surgical robot, and 20% for the commercialization of core products [4] - Additionally, about 10% will be used to expand production capacity, 8% for other products and in-development products, and 10% for potential strategic acquisitions, investments, or collaborations in the surgical robot industry [4] - The remaining 10% will be allocated for working capital and general corporate purposes [4]

Group 1 - The company, 精锋医疗-B, plans to conduct an initial public offering (IPO) from December 30, 2025, to January 5, 2026, offering 27.72 million H-shares at a price of HKD 43.24 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the 精锋® multi-port laparoscopic surgical robot and the 精锋® single-port laparoscopic surgical robot [1] - The company has reported revenue growth from RMB 48 million in 2023 to RMB 160 million in 2024, with sales costs increasing from RMB 19.6 million to RMB 61.9 million during the same period [2] Group 2 - The company has not achieved profitability, recording net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the years ending December 31, 2023, and 2024, and for the six months ending June 30, 2024, and 2025, respectively, primarily due to R&D expenses [2] - The company anticipates fluctuations in losses as it continues R&D, seeks regulatory approvals, and commercializes its products, with financial performance expected to vary due to uncertainties in clinical trials and commercialization success [3] - The company has secured cornerstone investment agreements totaling USD 75 million from various investors, including OrbiMed Genesis and Tencent, under certain conditions [3] Group 3 - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations of 42% for ongoing and planned R&D of core products, 20% for commercialization, 10% for capacity expansion, 8% for other products, and 10% for potential strategic acquisitions or investments in the surgical robot industry [4]

Group 1 - The company, Jingfeng Medical-B (02675), plans to conduct a global offering of 27.72 million H-shares from December 30, 2025, to January 5, 2026, with a share price of HKD 43.24 per share [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the multi-port and single-port laparoscopic surgical robots [1] - The company has reported a significant increase in revenue, from RMB 48 million for the year ending December 31, 2023, to RMB 160 million for the year ending December 31, 2024 [2] Group 2 - The company has incurred operating losses during the reporting periods, with net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the respective periods due to R&D expenses [2] - The company has entered cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for shares totaling USD 75 million under certain conditions [3] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations for R&D, commercialization, capacity expansion, and potential strategic acquisitions [4]

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

Core Insights - The company has achieved significant milestones in its robotic surgery product line, with a total of over 230 surgical robot orders, including more than 160 global commercial orders for its endoscopic surgical robot [1][2] - The company’s self-developed bronchoscopic surgical robot "Dudao" has received NMPA approval, further expanding its product offerings [1][3] Group 1: Order Growth and Market Presence - The company’s self-developed endoscopic robot "Tumi" has surpassed 160 global commercial orders, with approximately 120 new orders expected in 2025, indicating strong growth momentum [2] - In the domestic market, over 90% of the hospitals using Tumi are top-tier hospitals, with 23% being among the top 100 hospitals, reflecting a high level of market recognition [2] - The company is expanding its overseas presence, leveraging its established marketing network to penetrate over 40 countries across Asia, Europe, Africa, Oceania, and South America, with installations in 15 countries marking a significant milestone for domestic endoscopic surgical robots [2] Group 2: Product Line and Regulatory Approvals - The company has completed its portfolio of surgical robots, now offering five types: endoscopic (Tumi), orthopedic (Honghu), vascular (R-ONE), percutaneous (Mona Lisa), and bronchoscopic (Dudao), all of which have received NMPA approval [3] - Tumi, along with other products, has successfully obtained overseas registration certificates, accelerating the company’s international expansion [3] Group 3: Revenue Forecast - Revenue projections for the company are estimated to reach 500 million, 1.2 billion, and 1.8 billion yuan for the years 2025, 2026, and 2027 respectively, indicating a phase of rapid growth and impending volume increase [4]

Group 1 - The core investment opportunities in the medical device industry stem from innovation, international expansion, and mergers and acquisitions, with the sector's innovative and international capabilities being recognized and valuations undergoing reassessment [1] - The National Medical Products Administration has recently released a priority approval list for high-end medical devices, which includes brain-computer interfaces, ultra-high field MRI, and surgical robots, all of which are expected to benefit [1] - In the short term, there are opportunities for performance and valuation recovery for certain stocks in Q4 and 2026, with some companies set to release annual performance forecasts in January, suggesting a focus on those with either above or below expected performance [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovation Medicine Index (399275), which saw a daily fluctuation of 20%, focusing on innovative pharmaceutical sectors and selecting companies with high R&D investment and strong innovation capabilities [1] - The index aims to reflect the overall performance of leading companies in the pharmaceutical industry that combine growth potential with technological attributes, covering sectors such as biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [1]

Investment Rating - The report maintains an investment rating of "Positive" for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights that the spring market is expected to start, with a focus on brain-computer interfaces, surgical robots, and AI applications [2][3]. - The overall performance of the biopharmaceutical sector was weak last week, with a return of -0.18%, ranking 25th among 31 primary sub-industry indices [3][12]. - The report suggests that emerging industries such as brain-computer interfaces, surgical robots, and AI applications should be closely monitored as potential investment opportunities [3][12]. Market Performance - The biopharmaceutical sector's return over the past month was -1.95%, ranking 25th among 31 primary sub-industry indices [12][14]. - The medical device sector had the highest weekly return of 0.08%, while the pharmaceutical commercial sector had a return of -1.66% [12][32]. - The report notes that the brain-computer interface index and the robotics index saw five-day gains of 3.14% and 5.27%, respectively [3][12]. Policy Dynamics - The National Medical Products Administration issued regulations for the management of internet pharmaceutical and medical device information services, aiming to standardize the registration process [12][44]. - A national centralized procurement process for high-value medical consumables has been initiated, inviting eligible companies to participate [12][44]. Industry Trends - The report emphasizes the recovery of thematic investments in areas like brain-computer interfaces and surgical robots, with significant advancements in these fields [3][12]. - The report identifies key companies in the brain-computer interface sector, including companies like Mindray Medical and others [3][12]. - In the high-end medical device sector, companies such as Tianzhihang and Weigao Medical are highlighted for their growth potential [3][12]. Valuation Metrics - The current price-to-earnings (P/E) ratio for the biopharmaceutical industry is 29.13, slightly above the five-year average of 28.68 [14][19]. - The report indicates that the biopharmaceutical sector's P/E ratio has a premium of 117.10% compared to the Shanghai Composite Index [20]. Stock Performance - Notable stock performances include Hongyuan Pharmaceutical, which saw a significant increase of 59.43% last week, driven by strong market conditions [42]. - The report lists several companies with notable weekly and monthly performance metrics, providing insights into potential investment opportunities [43].